SG11201903162VA - Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use - Google Patents

Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use

Info

Publication number
SG11201903162VA
SG11201903162VA SG11201903162VA SG11201903162VA SG11201903162VA SG 11201903162V A SG11201903162V A SG 11201903162VA SG 11201903162V A SG11201903162V A SG 11201903162VA SG 11201903162V A SG11201903162V A SG 11201903162VA SG 11201903162V A SG11201903162V A SG 11201903162VA
Authority
SG
Singapore
Prior art keywords
composition
vagina
vaginal use
preparing
bacteriostatic agent
Prior art date
Application number
SG11201903162VA
Inventor
Zhongming Zeng
Wenyong Zhang
Kongyuan Wu
Original Assignee
Shenzhen Eulikan Biotechnology Co Ltd
Singapore Ze&Z Int Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Eulikan Biotechnology Co Ltd, Singapore Ze&Z Int Pte Ltd filed Critical Shenzhen Eulikan Biotechnology Co Ltd
Publication of SG11201903162VA publication Critical patent/SG11201903162VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to a use of an antimicrobial agent combination in preparing a composition for vagina. The combination of antimicrobial agents is strong in inhibiting against Escherichia coli, and/or Staphylococcus aureus, and/or Candida. The present disclosure also relates to a composition for vagina, which has a strong inhibition effect on Escherichia coli, and/or Staphylococcus aureus, and/or Candida. Being used in the vagina, the composition can promote the restoration of beneficial lactobacillus, increase the acidity of the vagina. It is suitable for modulating microecology and balancing microorganism in the vagina, and selectively decontaminating vagina.
SG11201903162VA 2016-10-09 2017-10-08 Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use SG11201903162VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610899657 2016-10-09
PCT/CN2017/105296 WO2018064978A1 (en) 2016-10-09 2017-10-08 Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use

Publications (1)

Publication Number Publication Date
SG11201903162VA true SG11201903162VA (en) 2019-05-30

Family

ID=61831934

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903162VA SG11201903162VA (en) 2016-10-09 2017-10-08 Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use

Country Status (7)

Country Link
US (1) US20190231748A1 (en)
EP (1) EP3520785A4 (en)
JP (1) JP6780123B2 (en)
CA (1) CA3039556C (en)
MY (1) MY191276A (en)
SG (1) SG11201903162VA (en)
WO (1) WO2018064978A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109589404A (en) * 2018-11-27 2019-04-09 杭州元研细胞生物科技有限公司 One kind is for anti-ageing reparation product of female reproductive system and preparation method thereof
CN109395062B (en) * 2018-12-29 2021-12-14 广州肽然生物科技有限公司 Female pudendum sterilization care solution
EP3714694A1 (en) * 2019-03-26 2020-09-30 Cosphatec GmbH Powder compositions comprising salts of c4 to c10 oxocarboxylic acids and of unsaturated or aromatic c6 to c10 carboxylic acids
CN111749023B (en) * 2019-03-28 2023-01-24 深圳市芭格美生物科技有限公司 Lysozyme non-woven fabric and preparation method thereof
CN110193004A (en) * 2019-04-28 2019-09-03 佛山市富馨科技实业有限公司 Women bacteriostatic gel and preparation method thereof containing biological bacteriostatic peptide
CN110656060B (en) * 2019-08-09 2020-08-07 四川厌氧生物科技有限责任公司 Multi-linked lactobacillus composition and application thereof in female vaginal health
CN112773780A (en) * 2019-11-11 2021-05-11 深圳优丽康生物技术有限公司 Composition for vagina and vulva and application thereof
WO2021133697A1 (en) * 2019-12-23 2021-07-01 Glyciome, Llc Microbiome optimization
CN115515556A (en) * 2020-02-12 2022-12-23 深圳优丽康生物技术有限公司 Bacteriostatic composition and preparation method and application thereof
WO2021160049A1 (en) * 2020-02-12 2021-08-19 深圳优丽康生物技术有限公司 Bacteriostatic composition, preparation method therefor and use thereof
DE202021104247U1 (en) * 2020-06-09 2021-09-24 G. Pohl-Boskamp Gmbh & Co. Kg Compositions for the prophylaxis and treatment of urinary tract infections and for cosmetic use
CN112870335A (en) * 2021-03-24 2021-06-01 广州修美生物科技有限公司 Bioactive composition, application thereof and tablet prepared from composition
CN114306108A (en) * 2022-01-17 2022-04-12 北京图灵微研生物科技有限公司 Nursing agent for balancing gynecological microecological flora structure

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670160A (en) * 1990-08-24 1997-09-23 Schulke & Mayr Gmbh Preservatives and their use
FR2738487B1 (en) * 1995-09-11 1997-11-28 Medix Lab ANTISEPTIC DERMATOLOGICAL COMPOSITION AND ITS MANUFACTURING METHOD
EP1432459A1 (en) * 2001-10-02 2004-06-30 Kimberly-Clark Worldwide, Inc. Inhibition of exoprotein production using aromatic compositions
CN100560071C (en) * 2002-08-12 2009-11-18 隆萨股份有限公司 Bactericidal composition
US7935732B2 (en) * 2004-04-08 2011-05-03 Isp Investments Inc. Antimicrobial compositions
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
GB0602325D0 (en) * 2006-02-06 2006-03-15 Remedy Res Ltd Virucidal compositions and uses
CN101744833B (en) * 2008-12-02 2012-05-23 济南宏瑞创博医药科技开发有限公司 Medicinal composition for treating bacterial vaginitis
CN101554463B (en) * 2009-05-26 2011-06-08 贵州本草堂药业有限公司 Drug for treating gynecologic and andrological diseases and preparation method thereof
AU2010305200B2 (en) * 2009-10-08 2014-10-02 Phlora Bio-Technology Investment Limited Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof
CA2890395C (en) * 2011-11-03 2021-03-16 The Trustees Of Columbia University In The City Of New York Botanical antimicrobial compositions
PT2814489T (en) * 2012-02-17 2017-10-23 Epitech Group S P A Compositions and methods for the modulation of specific amidases for n-acylethanolamines for use in the therapy of inflammatory diseases
AU2013370926B2 (en) * 2012-12-24 2017-08-24 Novapharm Research (Australia) Pty Ltd Improved antimicrobial compositions
CN104548071B (en) * 2015-01-27 2017-02-22 山西锦波生物医药股份有限公司 Recombinant human-derived collagen vagina gel for vaginal dryness and preparation method thereof

Also Published As

Publication number Publication date
JP6780123B2 (en) 2020-11-04
CA3039556A1 (en) 2018-04-12
US20190231748A1 (en) 2019-08-01
JP2019534896A (en) 2019-12-05
EP3520785A4 (en) 2020-05-27
EP3520785A1 (en) 2019-08-07
WO2018064978A1 (en) 2018-04-12
MY191276A (en) 2022-06-13
CA3039556C (en) 2021-06-15

Similar Documents

Publication Publication Date Title
SG11201903162VA (en) Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use
MX2022006525A (en) Lysin polypeptides active against gram-negative bacteria.
MX2017004091A (en) Composition and kits for inhibition of pathogenic microbial infection and methods of using the same.
MX2021009295A (en) Cannabidiol compositions and uses thereof.
MX2017012545A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
WO2016108045A3 (en) Antimicrobial compounds, compositions and methods
BRPI1012219C1 (en) product, substrate, pharmaceutical composition, uses of a product, and an antimicrobial peptide, methods to prevent biofilm formation in an environment, to treat a microbial infection by prophylaxis or therapy, and to treat or prevent biofilm formation in an environment, and, use of a cysteamine
WO2015003816A3 (en) Cystobactamides
WO2016004513A8 (en) Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
MX2016009251A (en) 7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents.
WO2015112980A3 (en) Dermaseptin-type and piscidin-type antimicrobial peptides
MX2015016319A (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections.
MX2019013763A (en) Biocide free preservation.
WO2016108930A3 (en) Antisense antibacterial compounds and methods
MX2017012535A (en) Novel heterocyclic compounds and their use in preventing or treating bacterial infections.
ZA202006612B (en) Antibacterial compounds
WO2016105510A3 (en) Methods and compositions for growth, storage, and use of bacterial preparations for wound and surface treatments
EA201991501A1 (en) ANTI-MICROBIAL COMPOSITION CONTAINING OLIGODYNAMIC METAL
ZA202002093B (en) Antibacterial compounds
MX2018006391A (en) Surface disinfectant with residual biocidal property.
MX2019014449A (en) Low-alcohol and sterilizable antimicrobial compositions and use thereof.
ZA202001605B (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MX2017012539A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
WO2015035234A3 (en) Anti-microbial compounds and compositions
PH12016501448A1 (en) Antifungal composition